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Abstract 
Effective dose (ED) estimation in CT examinations can be obtained by combining dose length product 
(DLP) with published ED per DLP coefficients or performed using software. These methods do not 
account for tube current (mA) modulation which is influenced by patient size.  
Aim 
To compare different methods of organ and ED estimation to measured values when using mA 
modulation in CT chest, abdomen and pelvis examinations.  
Method 
Organ doses from CT of the chest, abdomen and pelvis were measured using digital dosimeters and 
a dosimetry phantom. ED was calculated. Six methods of estimating ED accounting for mA 
modulation were performed using ImPACT CTDosimetry and Dose Length Product to ED coefficients. 
Corrections for the phantom mass were applied resulting in 12 estimation methods. Estimated organ 
doses from ImPACT CTDosimtery were compared to measured values. 
Results 
Calculated EDs were; chest 12.35 mSv (±1.48 mSv); abdomen 8.74 mSv (±1.36 mSv) and pelvis 4.68 
mSv (±0.75 mSv). There was over estimation in all three anatomical regions. Correcting for phantom 
mass improved agreement between measured and estimated ED. Organ doses showed 
overestimation of dose inside the scan range and underestimation outside the scan range. 
Conclusion 
Reasonable estimation of effective dose for CT of the chest and abdomen can be obtained using 
ImPACT CTDosimetry software or k-coefficients. Further work is required to improve the accuracy of 
ED estimation from CT of the pelvis. Accuracy of organ dose estimation has been shown to depend 
on the inclusion or exclusion of the organ from the scan range.  
  
Introduction 
Advances in technology have facilitated Computed Tomography’s (CT) expansion in providing rapid 
complex submillimetre imaging allowing more accurate diagnoses to be made [1-3]. In many 
instances CT is the first line investigation, however this has resulted in it becoming the dominant 
source of radiation risk/dose in medical imaging [3]. As with any medical imaging procedure 
involving radiation, there is a need for all involved to be aware of and monitor dose to patients; this 
is achieved by dose estimation as direct measurement of organ dose is not possible in the clinical 
environment. 
Effective dose is often calculated by combining dose length product [DLP], (the product of the CT 
dose index volume (CTDivol) and scan length) with published coefficients (k-coefficient) [4-7]. This 
approach uses data published by the American Association of Physicists in Medicine (AAPM) [4]. 
Critics of this method state that the use of tissue weighting factors from ICRP 60 and scanner data 
from as early as 1990 means that the coefficients lack relevance to modern multidetector scanners 
in use today [7]. Updated figures have been published and used by Elbakri and Kirkpatrick [5] and 
Huda et al [6].  Both these articles argued that due to the updated tissue weighting factors published 
by the ICRP the conversion factors require updating too. Huda et al [6] provide figures that are 
independent of the make and model of scanner whilst Elbakri and Kirkpatrick [5] argued that 
accuracy can be improved further by taking into account scanner-specific results. In Elbakri and 
Kirkpatrick’s paper figures for a range of scanner types are provided [5]. 
An alternative method of effective dose estimation can be performed by  combining CTDivol with 
data produced using Monte Carlo mathematical simulation. Data provided by the UK’s National 
Radiological Protection Board (NRPB) can be used to calculate effective dose by utilising ImPACT’s CT 
dosimetry tool (CTDosimetry V1.0.4) [8]. Although convenient, the data used in the Monte Carlo 
simulation was generated from early CT systems (not multidetector) therefore effective dose 
estimation has to be performed by fitting the characteristics of newer scanners to older designs [9]. 
This has the potential to introduce error [10].  
Tube current modulation (mA modulation) is not taken into account when dose estimations are 
performed using the software or k-coefficients. mA modulation is standard on modern CT imaging 
equipment and it has the ability to manipulate the exposure and therefore dose as the patient is 
imaged. The ability to accurately estimate dose using fixed tube current has been shown but organ 
dose generally decreases with the use of tube current–modulated acquisition and this should be 
taken into account in any estimation method, but patient size can directly affect the dose reduction 
achieved [11].  
The Medical Internal Radiation Dose (MIRD) mathematical phantom used in the development of the 
k-coefficients by the AAPM, Elbakri and Kirkpatrick and Huda et al and the stylised/mathematical 
phantom used in ImPACT’s dosimetry tool  represents a patient mass of 70 kg which is regarded as a 
low in comparison to modern demographics [4-6, 8, 12]. Research by Castellano stated that there is 
a change in effective dose for a change in mass with effective dose lower in larger patients for the 
same imaging parameters [13]. Castellano provides ratios for scaling effective dose using 70 kg as 
the reference value. The scaling factors indicate a 13% decrease in effective dose per 20 kg increase 
in mass for chest and abdomen CT acquisitions and a 9% decrease in effective dose per 20 kg 
increase in mass for pelvis acquisitions. For fixed exposure parameters, effective dose decreases as 
patient mass increases suggesting that dose is likely to be overestimated [13]. 
This initial work utilised a single scanner type and phantom size and with a focuses on organ and 
effective dose calculation accuracy using mA modulation in CT of the chest, abdomen and pelvis. 
This paper examines different methods of dose estimation and compares these to direct 
measurements of organ doses made using an anthropomorphic phantom and MOSFET dosimeters. 
Effective dose calculations were compared against values generated using k-coefficients and ImPACT 
software. To account for mA modulation mass weighted corrections were applied in an attempt to 
improve accuracy for effective dose calculations. 
 
Method 
For CT of the chest, abdomen and pelvis twelve methods of estimating effective dose were used 
(Table 1) CT dosimetry software published by the ImPACT CT scanner evaluation group (ImPACT 
CTDosimetry spreadsheet v 1.0.4, ImPACT, London, UK) was used to estimate organ and effective 
dose. For each anatomical region, the DLP was recorded. Dose per DLP figures published by the 
American Association of Physicists in Medicine (AAPM) [4], Huda et al [6] and Elbakri and Kirkpatrick 
[5] were used to calculate effective dose (Table 2Table 2). One method of calculating effective dose 
from directly measured organ doses using MOSFETs was undertaken for CT of the chest, abdomen 
and pelvis using  MOSFET dosimeters (Best Medical Canada, Kanata, Canada) and a male ATOM 
dosimetry phantom model 701-D (CIRS Inc. Virginia, USA). In all cases a Toshiba Aquillion 16 
Multidetector CT scanner was used (Toshiba medical systems, Otawara-Shi, Japan). This system 
utilises filtered back projection reconstruction and for the purpose of the data collection 
manufacturer recommended reconstruction algorithms and a mA standard deviation of 5. The CT 
system uses Toshiba’s SUREExposure3D method of tube current modulation during exposure. This 
uses the anterior-posterior and lateral scan plan radiograph to ascertain the optimum exposure. The 
system modulates the tube current  in the z-axis and during rotation [14]. 
Direct dose measurements (MOSFET) were taken as the gold standard against which estimation 
methods were compared [15, 16].  
Table 1 Methods of dose estimation 
1. ImPACT effective mA 
2. ImPACT average mA 
3. ImPACT mA modulation 
4. AAPM k-coefficient 
5. Huda et al k-coefficient 
6. Elbakri and Kirkpatrick k-coefficient 
7. Mass corrected ImPACT effective mA 
8. Mass corrected ImPACT average mA 
9. Mass corrected ImPACT mA modulation 
10. Mass corrected AAPM k-coefficient 
11. Mass corrected Huda et al k-coefficient 
12. Mass corrected Elbakri and Kirkpatrick k-coefficient 
 
  
 
Table 2 Coefficients for calculation of effective dose from DLP 
 k-coefficient mSv/mGy.cm 
 AAPM [4] Huda et al [6] Elbakri and Kirkpatrick [5] 
Chest 0.014 0.017 0.020 
Abdomen 0.015 0.016 0.017 
Pelvis 0.015 0.018 0.017 
 
Dose measurement 
MOSFET dosimeters provide an accurate and reproducible method of collecting organ dosimetry 
data [17]. In this work four banks of five dosimeters were used (n=20).  Calibration was performed as 
per manufacturer instructions at a tube voltage of 120 kV using the supplied calibration jig and a 
calibrated RaySafe X2 with R/F sensor (Unfors RaySafe AB, Bildal, Sweden). The error of these was 
2.01%.  
Indelible ink and radiopaque markers were used on an adult ATOM dosimetry phantom to ensure 
reproducible and accurate positioning and scanning of the phantom. MOSFET detectors were 
located within the phantom in the positions corresponding to the critical organs required for 
effective dose calculations [18-20] (see Table 3). Dose measurement was performed in 20 locations 
at a time as a total of 20 MOSFET sensors were available (Figure 1). In total 269 locations were used 
to measure organ dose and compute effective dose. For each MOSFET position, three exposures 
were made and a mean and standard deviation calculated to minimise random error.  
 Figure 1 Flow diagram illustrating the data collection process for dose measurement  
 
 
 
 
 
 
 
 
 
 
 
Table 3 Table stating the number of MOSFET locations used for organ dose measurement 
Organ Number of dosimeter locations  
Adrenals 2 
Bladder 16 
Brain 11 
Breast 2 
Active bone Marrow  85 
Clavicle 20,  
Cranium 4 
Cervical Spine 2 
Femora 4 
Mandible 6 
Pelvis 18 
Ribs 18 
Scapula
o
 9 
Sternum 4 
Thoraco-lumbar Spine 9 
Gall Bladder 5 
Heart 2 
Intestine (Small and large) 16 
Colon 11 
Small intestine 5 
Kidneys 16 
Liver 30 
Lungs 36 
Oesophagus 3 
Pancreas 5 
Prostate 3 
Spleen 14 
Stomach 11 
Testes 2 
Thyroid 10 
Thymus 4 
 locations in the anterior of C2 and upper oesophagus were used to calculate extra thoracic 
organ dose 
 locations in the left and right lingula of the mandible and to the left and right of the 
sublingual fossa were used to calculate salivary gland organ dose 
×
 locations in the left and right lingula of the mandible were used to calculate oral mucosa 
organ dose 
o
 locations in close proximity to the left and right glenoid fossa were used for dose to the upper 
humeri 
  
For each scan, the dose length product (DLP) and the recorded effective mAs were noted. The mean 
DLP was calculated. Axial images were reconstructed at 1 mm slices to match the acquisition’s 
collimation. The mAs values for each axial image were recorded and an average mAs was calculated 
(Table 4).  
Table 4 Imaging parameters 
 Chest Abdomen Pelvis 
kV 120 120 120 
Auto mA standard deviation 5 5 5 
Rotation time (s) 0.5 0.5 0.5 
 235 235 235 
  203.21 201.41 211.34 
Acquired slice thickness 
(detector length in z-axis) 
16 x 1 mm 16 x 1 mm 16 x 1 mm 
Pitch 0.938 0.938 0.938 
	
  904.49 792.72 791.76 
  33.2 33.2 33.2 
 
Comparison of ATOM and ImPACT standard phantoms 
The ATOM phantom and the standard phantom within the ImPACT CT dosimetry software are of 
different dimensions. To compensate, scaling of the ImPACT phantom was performed. The ATOM 
phantom from the apex of the skull to the upper border of the symphysis pubis was measured at 830 
mm. The length of the ImPACT standard phantom between the same reference points was 890 mm. 
Therefore a 1 mm slice in the ATOM phantom equated to a 1.07 mm slice in the standard phantom 
ImPACT CT dosimetry software. The proportions of the chest, abdomen and pelvis were compared to 
ensure that accurate comparisons were being made; Figure 2 illustrates good agreement between 
the two phantoms’ proportions for these. 
 
Figure 2 Comparison of the proportions of the chest, 
(left) has been scaled by a factor of 1.07 
 
The phantom used in ImPACT’s CT dosimetry software 
for effective dose calculations is 
phantom has a mass of 73 kg and consists of the head and torso only. Acc
accounts for only 55.4 % of total 
 
Table 4 Relative weight of body segments for an adult male 
Region/limb 
Torso 
Head and Neck 
Upper legs 
Lower legs 
Feet 
Upper arms 
Lower arms 
Hands 
TOTAL 
 
Using the data, a total body mass of the 
much greater at 131.8 kg; an increase in mass of 88.29%
was created to calculate the correction factor for mass. 
relationship remained constant (
abdomen and pelvis of the two phantoms. 
relative to the software phantom 
that was used in the development of 
based on a whole body mass of 70 kg [5, 6, 8, 21
ording to 
body mass [22] (Table 5).  
[22] 
Percentage contribution to total body mass (%)
48.3 
7.1 
21.0 
9.0 
3.0 
6.6 
3.8 
1.2 
100 
ATOM phantom was calculated. The resulting 
. Using the work of Castellano
An assumption was made that this
R
2
=1).  
 
The dosimetry phantom 
the DLP 
]. The ATOM 
Tozeren this 
 
mass was 
 [13] Figure 3 
 
  
Dose calculations using ImPACT CT Dosimetry software was performed in three ways;   
(i) Using the effective mAs quoted by the scanner for the full range of the acquisition,  
(ii) Using the average mAs for the full range of the acquisition,  
(iii) Using the mAs for each axial slice and summing the organ and effective doses to give 
final figures.  
For method 3 in Table 1 a macro was created to be used within the ImPACT Excel spreadsheet that 
calculated the start and finish position for each slice and the corresponding mAs to calculate the 
effective dose per slice, which was then summated for the whole scan. The Toshiba Aquillion 16 has 
an overbeaming requirement of 2 rotations (1 at each end of the scan) [23]. With a collimation of 
16x1 mm and a pitch of 0.938 an additional 15.0 mm at each end of the scan is required. When 
scaled, this is equivalent to 16.05 mm at the start and end of the acquisition in the simulation. The 
mA for the first and last slices was used as the mA for the respective upper and lower overbeamed 
sections of the scan for the mA modulation calculation. Comparisons between mass corrected and 
non-corrected figures using data from Table 5Table 4 were made.  
 
Comparison of Organ doses 
Effective dose is calculated by summing the weighted equivalent organ doses. Any difference in 
measured and estimated organ doses would be carried through into the final effective dose 
estimations. Comparison of estimated and measured organ doses was carried out to establish any 
sources of error. Unlike methods using DLP and conversion factors, dose estimation using ImPACT CT 
Dosimetry software allows figures for organ dose to be collated so this comparison could only 
analyse dose estimations using ImPACT CT Dosimetry software. It was also not feasible to correct for 
mass as accurate estimation of the distribution of intrathoracic and visceral fat was not possible. The 
difference between simulated and measured organ doses was calculated for each method (i. ImPACT 
Figure 3 Graphs showing effective dose scaling coefficient calculations for the chest/abdomen and pelvis. 
effective mA. ii. ImPACT average mA. iii. ImPACT mA modulation). These values were compared 
statistically using a single factor ANOVA.  
 
Results 
Effective doses calculated from the MOSFET organ dose measurements (Figure 4) were 12.35 mSv 
(±1.48 mSv) for CT of the chest; 8.74 mSv (±1.36 mSv) for CT of the abdomen and 4.68 mSv (±0.75 
mSv) for CT of the pelvis.  
 
Figure 4 Calculated effective dose 
 
 
Table 6 and Figure 5 illustrate the comparison of effective dose between measured and calculated 
values, with and without correction of phantom mass. Figure 5 demonstrates that using mass 
corrected values leads to greater accuracy for the calculated effective dose in comparison to the 
measured values.  
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Table 5 Effective dose measurement and calculation methods. 
 Effective Dose (mSv) 
Method Chest Abdomen Pelvis 
Calculated (MOSFET) 
12.35  
(±1.48) 
8.74 
(±1.36) 
4.68 
(±0.75) 
Estimated (Uncorrected for mass) 
ImPACT effective mA 19.00 15.00 10.00 
ImPACT average mA 17.00 14.00 9.90 
ImPACT mA modulation 17.08 13.86 9.93 
AAPM conversion factors [4] 12.66 11.89 11.88 
Huda et al  conversion factors [6] 15.38 12.68 14.25 
Elbakri and Kirkpatrick conversion factors [5]  17.91 13.24 13.22 
Estimated (Corrected for mass) 
Mass corrected ImPACT effective mA 12.30 9.71 7.20 
Mass corrected ImPACT average mA 11.00 9.06 7.13 
Mass corrected ImPACT mA modulation 11.05 8.97 7.15 
Mass corrected AAPM conversion factors [4] 8.19 7.69 8.55 
Mass corrected Huda et al conversion factor [6] 9.95 8.21 10.26 
Mass corrected Elbakri and Kirkpatrick conversion factors [5] 11.59 8.57 9.51 
 
 
 
Figure 5a 
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Figure 5b 
 
Figure 5c 
Figure 5 Comparison of corrected and uncorrected effective dose estimations of the (a) chest (b) abdomen and (c) pelvis to calculated effective dose 
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Comparison of estimated organ for CT of the chest, abdomen and pelvis is shown in Table 7. A very 
strong positive correlation between the three estimation methods (r>0.99) and no significantly 
statistical difference is shown (Single Factor ANOVA, p>0.9).  
 
  
Table 6 Comparison of estimated organ doses using mean, effective and modulated mAs for CT of the chest, abdomen and Pelvis. 
  
   Organ dose (mGy) 
Chest Abdomen Pelvis 
 
Measured 
ImPACT CTDosimetry 
Measured 
ImPACT CTDosimetry 
Measured 
ImPACT CTDosimetry 
Organ    
 
                 
Gonads 0.04 0.00 0.00 0.00 0.16 0.07 0.07 0.07 5.58 37.00 39.00 36.00 
Bone Marrow 8.10 12.00 14.00 12.22 4.55 8.50 9.30 8.59 5.45 10.00 10.00 10.01 
Colon 0.51 0.35 0.40 0.32 14.3 19.00 20.00 18.76 16.6 23.00 24.00 22.81 
Lung 24.7 45.00 52.00 45.27 5.48 9.50 10.00 9.44 0.16 0.04 0.05 0.04 
Stomach 11.3 8.80 10.00 7.87 26.0 41.00 45.00 40.78 2.02 1.00 1.10 1.04 
Bladder 0.09 0.02 0.02 0.02 1.93 1.10 1.20 1.16 19.8 47.00 49.00 47.93 
Breast 27.7 35.00 40.00 36.79 1.47 1.80 2.00 1.79 0.08 0.04 0.04 0.04 
Liver 18.9 14.00 17.00 12.71 22.4 38.00 41.00 37.70 0.71 0.62 0.65 0.62 
Oesophagus 22.7 53.00 61.00 53.35 3.02 1.40 1.60 1.43 0.07 0.01 0.01 0.01 
Thyroid 16.3 8.00 9.30 8.39 0.37 0.14 0.16 0.14 0.05 0.01 0.01 0.01 
Brain 0.32 0.30 0.35 0.31 0.01 0.01 0.01 0.01 0.03 0.00 0.00 0.00 
Salivary Glands 2.41 0.30 0.35 0.31 0.39 0.01 0.01 0.01 0.07 0.00 0.00 0.00 
Remainder 11.0 13.00 15.00 12.84 11.7 19.00 21.00 19.27 4.09 6.90 7.20 7.00 
 
  
Discussion  
The options of mA value that are used within the ImPACT CTDosimetry software values (effective, 
average or modulated) has an insignificant effect on the estimated effective dose with the 
coefficient of variation of 6.4%, 4.4% and 0.5% for the chest, abdomen and pelvis respectively. 
Establishing the mAs per slice is a time consuming process and for convenience, the effective mAs 
can be used when estimating effective dose using ImPACT CTDosimetry software. This value is easily 
obtained from CT imaging equipment. 
With the exception of the AAPM k-coefficient, uncorrected effective dose was over estimated 
(Figure 5). There was closer agreement for the CT of the chest (Figure 5a) with over estimation 
ranging from 2.48% to 42.4% (0.31 mSv to 6.65 mSv). There was poorer agreement in the abdomen 
(Figure 5b) and pelvis (Figure 5c) with over estimation of 30.54% to 52.74% (3.15 mSv to 6.26 mSv) 
and 72.48% to 101% (6.26 mSv to 9.57 mSv) respectively.   
Tube current modulation takes into account patient size within set parameters. The phantom used in 
this study is larger than the phantom used within ImPACT’s software and in the development of the 
k-coefficients therefore effective dose should be lower [4-6, 13]. Correcting for mass improved 
agreement between the effective dose estimations and calculations. Differences were -40.51% to -
0.41% (-4.16 mSv to 0.05 mSv) in the chest, -12.78% to 3.60% (-1.05 mSv to 0.32 mSv) in the 
abdomen. It can be seen from Figure 5a,b and c that the majority of the mass corrected values fall 
within the error of the MOSFET dosimeters indicating no significant differences between the 
calculated and estimated values. Effective dose for the pelvis (Figure 5c) showed the greatest 
disagreement after correcting for mass with differences to MOSFET ranging from 41.76% to 74.70% 
(2.47 mSv to 5.58 mSv). The disagreement between effective dose of the pelvis suggests that the 
correction factor used is requires further research utilising phantoms of different sizes.  
ANOVA showed no statistical difference in the estimation of organ dose using the average, effective 
or modulated mA (p=0.9). Using the mean of these three methods a comparison of estimated and 
measured organ doses shown in Table 7 highlights a pattern. It is apparent that organs within the 
scan range have an average estimate that is higher than measured values and those organs outside 
the scan range i.e. those organs whose dose comes from scattered radiation, have estimates that are 
lower than the measured values. To explore the effect this would have on effective dose estimations 
and calculations the tissue weighting factors were applied and the percentage contribution to 
effective dose of organs within and outside the scan range was calculated (Table 8). It is recognised 
that certain organs would be part in and part out of the scan range but for the purpose of this 
analysis, organs that were mostly in the scan range were classified as ‘in’ and vice versa.     
Table 7 Percentage contribution of organs inside and outside the scan range to effective dose calculations 
 Percentage contribution to calculated effective dose (%) 
 inside outside 
Chest 71.5 28.5 
Abdomen 58.5 41.5 
Pelvis 91.4 8.6 
 
 
The chest and abdomen show better balance between contributions of organs inside and outside 
the scan range which would explain why these estimations are in closer agreement when compared 
to the chest and pelvis. The pelvis, however, has an imbalance with the greatest contribution to the 
effective dose calculation coming from organs inside the scan range- specifically the bladder, gonads 
and colon. With the suggested tendency of ImPACT dosimetry software to over-estimate organ dose 
inside the primary beam the reason for the large difference in calculated effective dose using 
measured organ dose to estimated effective dose is apparent. Reasons for these errors require 
further investigation and should focus on the suitability of the Monte Carlo data sets used in 
ImPACT’s CTDosimetry software, the “best-fitting” of newer scanners to data in the ImPACT 
CTDosimetry software. 
Limitations 
It is recognised that this work is not without limitations. Only one scanner type and phantom was 
used. The tube current modulation parameters remained constant through the data collection and 
only filtered back projection reconstruction was used. Investigation into the mass correction for CT 
of the pelvis is required as this work has shown that over estimation occurs even after correction for 
mass.  Should accurate organ dose estimations be required, clinicians should be aware of the under 
and over estimation of dose for organs inside and outside the scan range. 
 This work has shown that in this context, there is the potential to improve the accuracy of effective 
dose estimations by accounting for patient mass. Further work is required improve the accuracy of 
the mass correction factor of the pelvis and externally validate the factors for the chest and 
abdomen. Experimentation using phantoms of different sizes, imaging parameters and CT scanners 
from different manufacturers is planned.  
 
Conclusion 
This work has shown that a for this scanner type and exposure parameters a reasonable estimation 
of effective dose for CT of the chest and abdomen can be obtained using ImPACT CTDosimetry 
software or the k-coefficients referenced.  The use of the k-coefficients is the quicker method 
compared to using ImPACT software but these do not give an indication of organ doses. This work 
has shown that there is a pattern for overestimation of organ dose inside the scan range and 
underestimation outside the scan range. Additional investigations using other scanners are required 
to establish if this is a consistent pattern. Further work is required to improve the accuracy of the 
mass correction factor for the pelvis and to test the external validity of the method varying the mass 
of the phantom and across different makes and models of CT scanner.  
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